Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ:BIOR)

0.5597 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company’s current target 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
Average bioavailability greater than 50% with high consistency observed in animal study 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administration 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
Company is on track to move into the clinic with its lead targeted therapeutics program 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Reverse Stock Split
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora Therapeutics 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces $9.75 Million Direct Offering
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients
Data Presented at the ACG Annual Meeting Demonstrates Successful Detection of Colon Entry and Topical Coverage Throughout Portion of Colon Implicated in Patients with Active Ulcerative Colitis 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022
Presents Results on Device Performance Studies in Humans for Targeted Therapeutics Platform 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
Further Demonstrating Possibilities for Systemic Delivery of Large Molecules 
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.